| Schedule of Segment Information |
The following represents
selected financial information for our segments for the years ended October 31, 2020 and 2019:
| |
|
Year Ended October 31, |
|
| |
|
2020 |
|
|
2019 |
|
| Net loss: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(2,241,443 |
) |
|
$ |
(5,074,868 |
) |
| Cancer Vaccines |
|
|
(828,136 |
) |
|
|
(677,450 |
) |
| Anti-Viral Therapeutics |
|
|
(1,168,969 |
) |
|
|
- |
|
| Cancer Diagnostics |
|
|
(5,836,594 |
) |
|
|
(5,196,471 |
) |
| Patent Licensing |
|
|
(17,221 |
) |
|
|
(869,863 |
) |
| Total |
|
$ |
(10,092,363 |
) |
|
$ |
(11,818,652 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
9,978,202 |
|
|
$ |
12,140,005 |
|
| Less non-cash share-based compensation |
|
|
(4,137,460 |
) |
|
|
(5,713,746 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
5,840,742 |
|
|
$ |
6,426,259 |
|
| |
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash share based compensation: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
1,141,542 |
|
|
$ |
2,212,090 |
|
| Cancer Vaccines |
|
|
365,681 |
|
|
|
458,392 |
|
| Anti-Viral Therapeutics |
|
|
739,140 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
3,581,377 |
|
|
|
2,689,761 |
|
| Patent Licensing |
|
|
13,002 |
|
|
|
1,066,016 |
|
| Total |
|
$ |
5,840,742 |
|
|
$ |
6,426,259 |
|
| |
|
October 31, |
|
| |
|
2020 |
|
|
2019 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
2,988,124 |
|
|
$ |
2,382,460 |
|
| Cancer Vaccines |
|
|
946,923 |
|
|
|
489,881 |
|
| Anti-Viral Therapeutics |
|
|
2,464,361 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
2,869,529 |
|
|
|
2,921,784 |
|
| Patent Licensing |
|
|
184,027 |
|
|
|
499,568 |
|
| Total |
|
$ |
9,452,964 |
|
|
$ |
6,293,693 |
|
|